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Os ​teoarthri ​tis (OA) has tra​di​tion ​ally been viewed as a non-in ​flam​ma​tory arthropa​thy and has not been con ​sid​ered a ‘se​ri​ous
dis ​ease’. How ​ever, this view has rad ​i​cally changed in re ​cent years, due to the com ​plex ​ity and het​ero ​gene​ity of the pa ​tient pop ​u​-
la​tions, spi​ralling so ​cio-eco ​nom​i​cal costs and long-term im ​pact on the qual ​ity of life of af ​fected in ​di​vid ​u​als. There is an acute
need for ob ​jec​tive and non-in ​va​sive di​ag ​nos ​tic bio ​mark ​ers in OA, mark ​ers that can strat ​ify pa​tient sub ​types and thereby di ​rect
ther ​a​peu ​tic treat ​ments at an ear ​lier dis ​ease stage (read per ​sonal health care (PHC)) (Conaghan, 2013). In ​creased in ​ter ​est in the
de​vel​op​ment of new di ​ag ​nos ​tic and prog ​nos ​tic tests for early forms of OA may in ​cor ​po​rate the use of blood-based bio ​mark ​ers;
how ​ever, both re​search and reg ​u​lated de​vel​op​ment and ap ​proval are still needed to reach a di ​ag ​nos ​ti​cally im​por ​tant sig ​nif ​i​cant
point where a given bio ​marker will ben ​e​fit the clin ​i​cal man ​age​ment of the pa ​tient.
1. The OA Biomarker Landscape Today
There are cur ​rently no dis ​ease-mod ​i​fy ​ing os ​teoarthri ​tis drugs (DMOAD) avail​able for treat ​ment of OA pa​tients (Mobasheri,
2013; Qvist et al., 2008). This may be due to the het ​ero ​gene​ity of the OA pop ​u​la​tion, where the ori ​gin and dri​ver of dis ​ease pro ​-
gres ​sion is of ​ten poorly un ​der ​stood. The main treat ​ment op ​tions for OA presently are pain re ​lief, phys ​i​cal ther ​apy and nu ​tri​tional
sup​ple​ments (nu ​traceu ​ti​cals). How ​ever, none of these can halt or re ​verse dis ​ease pro ​gres ​sion. In ad ​di​tion, di​ag ​no​sis is of​ten sub ​-
jec​tive, due to the lack of ob ​jec​tive, pre​cise and ac ​cu ​rate di​ag ​nos ​tic de​vices. Thus the lim ​ited clin ​i​cal di​ag ​no​sis and char ​ac​ter ​i​za​-
tion of the in ​di​vid ​ual pa​tient will ad ​versely in ​flu ​ence health ​care man ​age​ment and the re ​cruit​ment of the right pa ​tient co ​horts for
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the test​ing of drugs in clin ​i​cal tri​als. There is a med ​ical need for ob ​jec​tive, pre​cise and ac ​cu ​rate in vitro di​ag ​nos ​tic de​vices for
clin ​i​cal trial en ​rich ​ment (Kraus et al., 2015; Karsdal et al., 2013).
2. What Is the Medical Need for Biomarkers?
The lack of ap ​proved DMOADs in OA drags a long tail of failed clin ​i​cal drug tri​als. Re​cently the US Food and Drug Ad​min ​-
is ​tra​tion (FDA), the Eu ​ro ​pean Med ​i​cines Agency (EMA) and other reg ​u​la​tory agen ​cies have pub ​lished guide​lines on how bio ​-
mark ​ers should be de​fined. Dif ​fer ​ent groups and pub​lic-pri​vate part​ner ​ships have pro​posed dif​fer ​ent mod ​els for clas ​si​fy ​ing OA
bio ​mark ​ers for clin ​i​cal use (Bauer et al., 2006; Kraus et al., 2011; Bay-Jensen et al., 2016a,b). There is a gen ​eral con ​sen​sus on
the med ​ical need for bio ​marker de​vel​op​ment which may be sum ​ma​rized as seven key points:
1. Trans ​la​tional bio ​mark ​ers, which al​low bet​ter char ​ac​ter ​i​za​tion of a drug in pre​clin ​i​cal de​vel​op​ment, en ​sur​ing of se​lec​tion of
the most vi​able pro ​jects
2. Early iden ​ti​fi​ca​tion of ef ​fi​cacy of in ​ter ​ven ​tion; Go/​​no-go de​ci​sion-mak ​ing al​ready in phase 1b/​​2a stud ​ies, which nor ​mally do
not in ​clude ef ​fi​cacy mea ​sures.
3. Phase II and Phase III trial en ​rich ​ment; re​duc​tion in study size, and a par ​tic​u​lar OA phe​no​type tai​lored for a se​lec​tive in ​ter ​-
ven ​tions, which will re​cuse length of the clin ​i​cal study to al​low more ef ​fi​cient and less costly tri ​als
4. Iden ​ti​fi​ca​tion of pa​tients who are fast pro ​gres ​sors and as such in great​est need of treat ​ment.
5. Iden ​ti​fi​ca​tion of su ​per re​spon​ders to a spe​cific treat ​ment; pa​tients with high ef ​fi​cacy and low safety con ​cerns
6. Bio ​mark ​ers of dis ​ease ac​tiv ​ity; as OA is not a sta​bile dis ​ease, there is a need for de ​vices for iden ​ti​fi​ca​tion with high dis ​ease
ac​tiv ​ity and po ​ten ​tial pro ​gres ​sion
7. Easy ac​ces ​si​ble mon ​i​tor ​ing de​vices – point of care; post mar ​ket​ing pa​tient care and per ​son​al​ized med ​i​cine
Al​though there are clear over ​laps in the above, it is clear that no sin ​gle bio ​marker will be the an ​swer for all.
3. Message From the Regulators
The pub ​lic at ​ten ​tion to bio ​mark ​ers is in ​creas ​ing, re​cently fur ​ther em ​pha​sized by the “white house” ini​ti​ate fo ​cus ​ing on quan ​-
tifi​able tools for pa ​tient elec ​tion and mon ​i​tor ​ing.  On the reg ​u​la​tory side, the FDA is ​sued a po ​si​tion doc​u​ment de​scrib ​ing the
need and road ahead for per ​son​al​ized med ​i​cine “FDA: Paving the Way for Per​son​al​ized Med ​i​cine”,  which later re​sulted in new
guide​lines to faster bio ​marker tool de ​vel​op​ment by the guide ​lines “Iden ​ti​fy ​ing Po ​ten ​tial Bio ​mark ​ers for Qual​i​fi​ca​tion and De​-
scrib ​ing Con​texts of Use To Ad​dress Ar​eas Im​por ​tant to Drug De​vel​op​ment”,  which are in ad ​di​tion to the stan ​dard guide​lines
for in vitro com​pan ​ion di​ag ​nos ​tic de​vice. This has led to the dis ​cus ​sion on prospec​tive-ret ​ro ​spec​tive bio ​marker analy ​sis for reg ​-
u​la​tory con ​sid​er ​a​tion, by the white pa​per from the in ​dus ​try phar ​ma​coge​nomics work​ing group (Patterson et al., 2011). This will
greatly as ​sist pre​ci​sion med ​i​cine and PHC by guid ​ing the dis ​cus ​sion on how to im ​ple​ment a “prospec​tive-ret ​ro ​spec​tive bio ​-
marker analy ​sis”. The prospec ​tive-ret​ro ​spec​tive bio ​marker analy ​sis ap​proach is de ​vel​oped to “res ​cue” failed phase III tri ​-
als. Qual​i​fied bio ​mark ​ers are to be mea ​sured in cer ​ti​fied, high-qual ​ity lab ​o​ra​to ​ries and an ​a​lyzed us ​ing pre​de​fined sta​tis ​ti​cal
analy ​sis plans to test hy ​pothe​ses re​lated to ret ​ro ​spec​tive analy ​sis of tech ​ni​cally and bi ​o​log ​i​cally val ​i​dated bio ​mark ​ers.
Ac​cord ​ing to the FDA, a prog ​nos ​tic in vitro di​ag ​nos ​tic bio ​marker would need a 510 K or de novo ap ​proval (class II de ​vice),
whereas a pre ​dic​tive bio ​marker would need ldt pre-mar ​ket ap ​proval (PMA, class III de​vice). The main sep ​a​rat​ing fac​tor is that a
prog ​nos ​tic bio ​marker pro ​vides you with an es ​ti​mate for pro ​gres ​sion, whereas a pre​dic​tive bio ​marker would be used to de ​cide the
ex ​act treat ​ment reg ​i​men for in ​di​vid ​ual pa​tients, and would there ​fore have a sig ​nif ​i​cant im ​pact on the pa ​tien ​t's life. A pre ​dic​tive
bio ​marker will of ​ten be​come a com ​pan ​ion di​ag ​nos ​tic.  In ad ​di​tion, the re​cent “drug de​vel​op​ment tool (DDT) box” guide​lines
are also al ​low ​ing for reg ​u​la​tory as ​sess​ment of tools to as ​sist in clin ​i​cal drug de ​vel​op​ment, such as the fib ​rino ​gen en ​rich ​ment of
pa​tients in COPD clin ​i​cal stud ​ies with a more se ​vere out​come (fast pro ​gres ​sors), which is now clas ​si​fied as a DDT.
No bio​mark ​ers have yet been qual ​i​fied as bio ​mark ​ers for OA, how ​ever sev ​eral bio ​mark ​ers have been de ​vel​oped tar ​get​ing
car ​ti​lage degra ​da​tion and for ​ma​tion (e.g. CTX-II, ARGS, PI​IANP), joint in ​flam​ma​tion (e.g. C3M, Col2-NO2), bone re​mod ​el​-
ling (e.g. al​pha CTX I, os ​teo ​cal​cin) as well as in ​flam​ma​tion and meta ​bolic fac​tors (Bay-Jensen et al., 2016a,b). The sci​en ​tists
and clin ​i​cians work ​ing in the bio ​marker field can ​not ex ​pect a “one size fits all” so​lu ​tion for OA. Con ​se​quently it is im ​por ​tant to
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test and val​i​date a bio ​marker to a spe​cific hy ​poth ​e​sis. This can be done un​der the lab ​o​ra​tory-de​vel​oped test (LDT) (Sarata and
John​son, 2014), which is a type of in vitro di​ag ​nos ​tic test that is de ​signed, man ​u​fac​tured and used within a sin ​gle lab ​o​ra​tory.
4. How Do We Move Forward?
Dif​fer ​ent ap ​proaches, tech ​niques and bet​ter-strat​i​fied pa​tient sam​ples are needed to move bio ​marker de​vel​op​ment to ​wards
qual​i​fi​ca​tion, which means that new part ​ners need to come to ​gether and col ​lab ​o​rate. For ex ​am​ple de​vel​op​ment of a novel blood-
based and car ​ti​lage-de​rived pro ​tein bio ​marker re​quires ap ​pli​ca​tion of ad ​vanced an ​a​lyt​i​cal tech​niques such as pro​teomics and
mass spec​trom​e​try, whereas de​vel​op​ment of the bio ​marker as ​say re​quires knowhow of bio ​chem​i​cal and im ​muno ​log ​i​cal as​sess​-
ment plat ​forms. Fur ​ther ​more, test ​ing, val​i​da​tion and qual ​i​fi​ca​tion re​quires ac​cess to high qual ​ity clin ​i​cal sam ​ples from sev ​eral
in ​de​pen ​dent ret​ro ​spec​tive or prospec​tive co ​horts. In the end a com​mer ​cial​i​sa​tion plan needs to be es ​tab ​lished to push for​wards
and fi​nance the qual ​i​fi​ca​tion of bio ​mark ​ers. Thus it is most likely that no sin ​gle en ​tity, pub ​lic or pri ​vate, will be able to com ​plete
these de​vel​op​ment steps alone. There is a need for i) For ​ma​tion of pub ​lic-pri​vate part​ner ​ships to de​velop, test, val​i​date and qual​-
ify bio ​mark ​ers for use in clin ​i​cal trial and pa ​tient man ​age​ment, ii) De​sign of clin ​i​cal stud ​ies that strat ​ify pa​tients and in ​ves ​ti​gate
trends and char ​ac​ter ​is ​tics of spe​cific OA co ​horts and study pop ​u​la​tions, and iii) Col ​lab ​o​ra​tion be​tween biotech and phar ​ma​ceu ​ti​-
cal com ​pa​nies to sup ​port the com​mer ​cial​iza​tion of bio ​mark ​ers.
In sum​mary, a great deal of col ​lab ​o​ra​tive work needs to be done in this area to de ​velop more pre​dic​tive, prog ​nos ​tic, ob ​jec​tive
and com​ple​men ​tary bio ​mark ​ers for OA man ​age​ment and DMOAD de​vel​op​ment.
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